Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Vista sencilla de ítem
dc.creatorZost, Seth J.
dc.creatorGilchuk, Pavlo
dc.creatorChen, Rita E.
dc.creatorCase, James Brett
dc.creatorReidy, Joseph X.
dc.creatorTrivette, Andrew
dc.creatorNargi, Rachel S.
dc.creatorSutton, Rachel E.
dc.creatorSuryadevara, Naveenchandra
dc.creatorChen, Elaine C.
dc.creatorBinshtein, Elad
dc.creatorShrihari, Swathi
dc.creatorOstrowski, Mario
dc.creatorChu, Helen Y.
dc.creatorDidier, Jonathan E.
dc.creatorMacRenaris, Keith W.
dc.creatorJones, Taylor
dc.creatorDay, Samuel
dc.creatorMyers, Luke
dc.creatorEun-Hyung Lee, F.
dc.creatorNguyen, Doan C.
dc.creatorSanz, Ignacio
dc.creatorMartinez, David R.
dc.creatorRothlauf, Paul W.
dc.creatorBloyet, Louis-Marie
dc.creatorWhelan, Sean P. J.
dc.creatorBaric, Ralph S.
dc.creatorThackray, Larissa B.
dc.creatorDiamond, Michael S.
dc.creatorCarnahan, Robert H.
dc.creatorCrowe, James E.
dc.date.accessioned2020-07-17T14:43:49Z
dc.date.available2020-07-17T14:43:49Z
dc.date.created2020-07-10
dc.description.abstractenglishAntibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms.spa
dc.format.extent20 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41591-020-0998-xspa
dc.identifier.issn1546-170Xspa
dc.identifier.otherhttps://www.nature.com/articles/s41591-020-0998-x#article-infospa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/10725
dc.publisherScience Directeng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleRapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike proteinspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
s41591-020-0998-x.pdf
Tamaño:
4.03 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS